A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Gemcitabine (Primary) ; Indoximod (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors NewLink Genetics Corporation
- 03 Aug 2023 Results examining tissue-based correlates of treatment response and resistance using matched baseline and on-treatment biopsies collected from patients with PDA treated in the first-line metastatic setting, published in the Clinical Cancer Research
- 21 Feb 2019 Status changed from active, no longer recruiting to completed.
- 09 Nov 2018 Results presented in the NewLink Genetics Corporation media release.